Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 18.
doi: 10.1002/oby.70056. Online ahead of print.

Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study

Leslie J Heinberg  1 , Alexandra M Lee  2 , Gary D Foster  3 , Amy DiVita  4 , Matthew Allman  4 , Daniel Rotroff  5 , Carla Bou Dargham  5 , Michelle I Cardel  6   7   8
Affiliations

Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study

Leslie J Heinberg et al. Obesity (Silver Spring). .

Abstract

Objective: Limited data exist on telemedicine prescribing of semaglutide and tirzepatide. The effects of a telehealth obesity management program combining the provision of semaglutide and tirzepatide with a behavioral program tailored for long-acting antiobesity medications (AOMs) were evaluated.

Methods: In this single-arm study, 180 participants recruited from a telehealth medical obesity program received a virtual behavioral program tailored for long-acting AOMs, Bluetooth wireless scales, and a blood pressure (BP) cuff. Participants' (mean age = 44.1; 91% female; 81% White; mean weight = 102.8 kg) weight, BP, eating habits, dietary quality, physical activity, and side effects were assessed at baseline and at 12 and 24 weeks. Wilcoxon rank sum tests were conducted, and p values were adjusted using a false discovery rate approach. Intent-to-treat analysis was performed using last observation carried forward (LOCF).

Results: Weight loss was 7.2% (SD = 5.2%) at 12 weeks and 12.3% (SD = 6.9%) at 24 weeks (p < 0.0001). Mean BP declined from 131.0/83.8 (SD = 17.2/12.2) to 122.5/78.7 (SD = 13.7/10.1) at 12 weeks and 120.0/78.2 (SD = 13.5/10.6) at 24 weeks (p < 0.0001). Participants significantly improved their eating habits, diet quality, and activity. Side effects were markedly lower than in previously reported trials.

Conclusions: Virtually delivered treatment combining telemedicine and a behavioral program tailored for long-acting AOMs demonstrated clinically significant improvements in weight, BP, diet, and activity over 24 weeks.

Trial registration: ClinicalTrials.gov identifier: NCT06034457.

Keywords: behavior; intervention; lifestyle; obesity medication; telemedicine.

PubMed Disclaimer

References

    1. S. D. Emmerich, C. D. Fryar, B. Stierman, and C. L. Ogden, “Obesity and Severe Obesity Prevalence in Adults: United States, August 2021‐August 2023,” NCHS Data Brief no. 508 (2024), https://www.ncbi.nlm.nih.gov/books/NBK611097/pdf/Bookshelf_NBK611097.pdf.
    1. National Task Force on the Prevention and Treatment of Obesity, “Overweight, Obesity, and Health Risk,” Archives of Internal Medicine 160 (2000): 898–904.
    1. A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, et al., “Tirzepatide Once Weekly for the Treatment of Obesity,” New England Journal of Medicine 21, no. 3 (2022): 205–216, https://doi.org/10.1056/NEJMoa2206038.
    1. D. M. Rubino, F. L. Greenway, U. Khalid, et al., “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial,” JAMA 327, no. 2 (2022): 138–150.
    1. A. Montero, G. Sparks, A. Kirzinger, I. Valdes, and L. Hamel, “KFF Health Tracking Poll 2023: The Public's Views of New Prescription Weight Loss Drugs and Prescription Drug Costs,” published August 4, 2023, https://www.kff.org/health‐costs/kff‐health‐tracking‐poll‐july‐2023‐the‐....

Associated data

Grants and funding

LinkOut - more resources